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a  b  s  t  r  a  c  t
Multidrug  resistance  protein  1 (MRP1/ABCC1),  an  integral  transmembrane  efflux  transporter,  belongs
to the  ATP-binding  cassette  (ABC)  protein  superfamily.  MRP1  governs  the  absorption  and  disposition
of  a  wide  variety  of  endogenous  and  xenobiotic  substrates  including  various  drugs  across  organs  and
physiological  barriers.  Additionally,  its  overexpression  has  been  implicated  in multidrug  resistance  in
chemotherapy  of multiple  cancers.  Here,  we  describe  the  development  of  a  high content  imaging-based
screening  assay  for MRP1  activity.  This  live  cell-based  automated  microscopy  assay  is  very  robust  and
allows  simultaneous  detection  of cell  permeable,  non-toxic  and  potent  inhibitors.  The validity  of  the
assay  was  demonstrated  by profiling  a library  of  386  anti-cancer  compounds,  which  are  under  clinical
trials,  for  interactions  with  MRP1.  The  assay  identified  12  potent  inhibitors  including  two  known  MRP1
inhibitors,  cyclosporine  A and  rapamycin.  On  the  other  hand,  MRP1-inhibitory  activity  of  tipifarnib,
AZD1208,  deforolimus,  everolimus,  temsirolimus,  HS-173,  YM201636,  ESI-09,  TAK-733,  and  CX-6258
has  not  been  previously  reported.  Inhibition  of  MRP1  activity  was  further  validated  using  flow  cytometry
and  confocal  microscopy  for the  respective  detection  of  calcein  and  doxorubicin  in  MRP1-overexpressing
cells.  Among  the  identified  compounds,  tipifarnib,  AZD1208,  rapamycin,  deforolimus,  everolimus,  TAK-
733,  and  temsirolimus  resensitized  MRP1-overexpressing  H69AR  cells  towards  vincristine,  a cytotoxic
chemotherapeutic  agent,  by 2–6-fold.  Using  purified  HEK293  membrane  vesicles  overexpressing  MRP1,
MRP2,  MRP3,  and  MRP4,  we  also  demonstrated  that  the  identified  compounds  exert  differential  and
selective  response  on  the uptake  of  estradiol  glucuronide,  an  endogenous  MRP  substrate.  In summary,
we  demonstrated  the effectiveness  of  the  high  content  imaging-based  high-throughput  assay  for  profiling
compound  interaction  with  MRP1.
© 2017  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The ATP-binding cassette (ABC) transporters represent a large
evolutionarily conserved family of membrane proteins ubiqui-
tous in practically all living organisms. In the human genome, a
total of 48 ABC transporter genes have been identified and they
are classified into seven subfamilies, designated A–G [1]. Func-
tionally, ABC transporters are responsible for the transmembrane
efflux of a remarkably broad spectrum of substrates, including
ions, lipids, carbohydrates, peptides, and xenobiotics [1–3]. They
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are also well-known to regulate the absorption and disposition of
various therapeutic agents [4,5]. The importance of these trans-
porters is further underscored by the fact that mutations in ABC
transporter genes are associated with human diseases, including
Dubin–Johnson syndrome (ABCC2), pseudoxanthoma elasticum
(ABCC6), cystic fibrosis (ABCC7), persistent hyperinsulinemic hypo-
glycemia of infancy (ABCC8), gout (ABCG2), intrahepatic cholestasis
(ABCB4), schizophrenia (ABCA13), sitosterolemia (ABCG5 and
ABCG8), and Tangier disease (ABCA1) [6,7]. Owing to their roles in
regulating the absorption and disposition of various drugs, the US
Food and Drug Administration (FDA) has recommended the inves-
tigation of interactions between drug candidates and a number of
key ABC drug transporters [8]. Consequently, in the pharmaceutical
industry, profiling of drug interactions with ABC drug transporters
to determine a substrate/inhibitor relationship has become a stan-
dard component in the drug discovery process. This information
can be used not only in the early discovery process to filter candi-
http://dx.doi.org/10.1016/j.phrs.2017.02.024
1043-6618/© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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dates with undesirable interactions, but also during later stages of
drug discovery including lead optimization and pre-clinical evalu-
ation of compound toxicity and efficacy.
Multidrug resistance protein 1 (MRP1/ABCC1) is the second
ABC transporter identified in humans and was originally discov-
ered from a doxorubicin-selected drug-resistant lung cancer cell
line [9]. In the human body, MRP1 is primarily expressed in the
basolateral membrane of epithelial cells of organs such as the
lung, gastrointestinal tract, kidney, pancreas, testis, placenta, blad-
der, and adrenal gland [10]. Consistent with its expression profile,
MRP1 governs the absorption and disposition of a wide variety of
endogenous and exogenous substrates across organs and physio-
logical barriers, and serves to protect tissues from toxic molecules
[11]. Notable physiological substrates of MRP1 include organic
anions such as cysteinyl leukotriene (LTC4), estradiol glucuronide
(E217G), glutathione (GSH), and cobalamin [12–14]. MRP1 may
play a role in the pathogenesis of asthma and allergic reactions
due to its ability to efflux LTC4, a key pro-inflammatory signaling
molecule [15]. In addition, MRP1 can also affect the bioavailability
of various types of antivirals, antimalarials, and antibiotics [16].
MRP1, together with P-glycoprotein (P-gp/ABCB1) and breast
cancer resistance protein (BCRP/ABCG2), is a major ABC trans-
porter implicated in multidrug resistance (MDR), a phenomenon
characterized by the resistance of malignancies to structurally and
mechanistically distinct anti-cancer agents [17]. The involvement
of MRP1 in MDR  is consistent with the observation that MRP1
accommodates the efflux of conventional cytotoxic anti-cancer
agents, such as doxorubicin, etoposide, vincristine, and methotrex-
ate, as well as other newly developed anti-cancer agents that target
specific signaling pathways such as tyrosine kinase inhibitors [16].
Overexpression of MRP1 has been linked to MDR  in breast, lung,
and prostate cancers, and several types of leukemia [18–21]. In
addition, MRP1 overexpression has been shown to be predictive of
poor clinical outcome in soft tissue sarcoma of limbs and trunk wall
and primary neuroblastoma [22,23]. Interestingly, MRP1, together
with MRP3 and MRP4, has also been implicated in the progres-
sion of neuroblastoma through functions other than their efflux of
cytotoxic drugs [24].
Many in vitro assay systems have been developed to study
drug interactions with ABC transporters, typically using cell lines
overexpressing the transporter of interest or membrane vesicles
prepared from these [25]. One of the widely used methods for high
throughput screening of compound interaction with ABC trans-
porter is the cell-based accumulation or efflux assay that utilizes
a fluorescent substrate to probe if a test compound inhibits the
efflux of the substrate by an ABC transporter. Flow cytometry or
fluorescent plate reader are commonly used for the downstream
fluorescence quantification [26–29]. Fluorescence detection with
flow cytometry is generally more sensitive than fluorescent plate
reader, which is commonly limited by a narrow detection range
and high non-specific fluorescence background, and is typically
more suited for assays performed in a homogenous condition [30].
The use of flow cytometry, on the other hand, usually involves cell
washing and acquisition procedures that are more time-consuming
and thus less compatible with a high throughput setup. Another
commonly used assay for screening measures the uptake of a radi-
olabeled substrate into inside-out membrane vesicles expressing
the transporter of interest. This type of assay is not compati-
ble with intact cells and therefore cannot test the permeability
of the compounds of interest. In recent years, image-based high
content screening employing automated microscope platform has
gained increasing use in biomedical research due to its capability to
provide in situ visual data and to simultaneously study multiple bio-
logical targets [31]. Such strategy has recently been adapted for the
high content imaging-based efflux assay as a superior alternative
to flow cytometry- and fluorescent plate reader-based screening of
compound interaction with P-gp and BCRP [32,33].
In this study, we describe the development, optimization, and
validation of a high content imaging-based efflux assay to profile
drug interactions with MRP1. The assay is performed in live cells
and can be used to obtain information about modulation of target
activity, toxicity and autofluorescence of the test compounds. The
effectiveness of this assay is demonstrated by screening a unique
library of 386 anti-cancer compounds currently under clinical trials
targeting 12 types of cancers. The screening process identified 12
potent inhibitors including cyclosporine A and rapamycin, both of
which are known inhibitors of MRP1. We  validated the inhibitory
activity of the positive hits using established methods widely
used for ABC transporter studies and identified several anti-cancer
agents that have not been previously known to inhibit MRP1. The
ability of selected anti-cancer agents to reverse drug resistance in
an MRP1-overexpressing MDR  cell line is also demonstrated.
2. Materials and methods
2.1. Chemicals
Calcein-AM was purchased from Corning Life Sciences (Corning,
NY). MK571 was  acquired from Cayman Chemical (Ann Arbor, MI).
Adenosine monophosphate (AMP), adenosine triphosphate (ATP),
doxorubicin, estradiol 17-(-d-Glucuronide) (E217G), poly-d-
lysine, thiazolyl blue tetrazolium bromide (MTT) were procured
from Sigma-Aldrich (St. Louis, MO). [6,7-3H]E217G (49.9 Ci
mmol−1) was purchased from PerkinElmer (Waltham, MA). An
anti-cancer compound library consisting of 386 anti-cancer small
molecules under clinical trials for 12 different types of cancers was
procured from Selleck Chemicals (Houston, TX).
2.2. Cell lines and cell culture
H69, H69AR, and HEK293 cells were obtained from ATCC (Man-
assas, VA). HEK293T cells were kindly provided by Dr. Adam Hoppe
(South Dakota State University, Brookings, SD). HEK293/pcDNA3.1
and HEK293/MRP1 cells were kindly provided by Dr. Suresh V.
Ambudkar (NIH, Bethesda, MD)  and maintained as previously
described (Muller et al., 2002). HEK293 and H69 cell lines were cul-
tured in DMEM (GE Healthcare, Marlborough, MA)  and RPMI 1640
(ATCC), respectively, supplemented with 10% fetal bovine serum.
Cells were grown in a humidified incubator maintaining 5% CO2 at
37 ◦C. H69AR cells were challenged monthly with 0.8 M doxoru-
bicin and cultured drug-free for one week before use.
Using pTagRFP-N vector as a backbone, we generated a new two-
color human MRP1 construct using the similar cloning strategy as
described before [58]. A stop codon was  introduced after the MRP1
coding sequence into the two-color MRP1 construct to generate
GFP-MRP1 (Green fluorescent protein fused with MRP1). Two-color
MRP1 and GFP-MRP1 expression vectors were transfected into HEK
cells (Agilent, Santa Clara, CA) using jetprime transfection reagent
(VWR) according to the manufacturer’s instructions. After 24 h,
standard medium was  replaced with medium containing G418
(400 ug/ml). Cells were maintained under G418 selection for two
weeks. Then, the G418 amount was increased to 800 ug/ml. GFP
expressing cells were sorted from the non-expressing cells using
flow cytometry and maintained under G418 selection of 200 ug/ml.
2.3. MRP1 inhibition screening with automated image acquisition
and analysis
Initial assay development and optimization were performed in
H69 and H69AR cells with calcein-AM as the fluorescent substrate
and MK571 as the positive control for MRP1 inhibition. Screening of
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MRP1 inhibitors within the anti-cancer compound library was  car-
ried out using H69AR cells in 96-well Optical-Bottom Plates with
Polymer Base (ThermoFisher Scientific, Waltham, MA)  coated with
poly-d-lysine (Sigma-Aldrich, St. Louis, MO). Cells were seeded at
6 × 104 cells per well in 100 L culture medium and incubated
overnight. At the onset of drug treatment, culture medium was
removed and replaced with 80 L of serum-free medium. Pretreat-
ment was performed by adding 10 L of test compounds (10 M
final concentration), DMSO (0.2% final concentration) as negative
control, or MK571 (50 M final concentration) as positive control.
After 30 min, 10 L of calcein-AM (0.25 M final concentration)
was added and the cells were incubated for 1 h. At the end of
the incubation period, treatment was removed and the cells were
washed once with PBS before 100 L PBS containing 10 mM HEPES
and 4.5% glucose was added.
Bright-field and fluorescent images (233.28 × 233.28 M)  were
captured using an ImageXpress Micro XLS Widefield High-Content
Analysis System (Molecular Devices, Sunnyvale, CA) equipped with
a 0.70 numerical aperture 60 × objective. For each well, 4 bright-
field and 4 fluorescent images were taken. Fluorescent images
were acquired using a FITC filter with excitation and emission
wavelengths of 482/35 and 536/40 nm,  respectively, with an expo-
sure time of 100 ms.  It takes approximately 15 min  to scan an
entire plate. As the intracellular accumulation of calcein slowly
dropped over time after treatment was removed, one negative and
one positive controls were included in every two  columns of the
plate. Automated image analysis on fluorescent images was per-
formed using the MetaXpress software (version 5.10.41, Molecular
Devices). Segmentation of fluorescent objects on the FITC chan-
nel was carried out using a custom application module based on
the ‘Find Blobs’ module. The custom module identifies fluorescent
objects above a background fluorescent intensity and applies seg-
mentation masks based on set parameters for object size. Three
independent screening experiments were performed.
2.4. Flow cytometry-based calcein accumulation assay
H69 and H69AR cells were prepared in serum-free culture
medium to a density of 7 × 105 cells/mL. The assay was  performed
by incubating 1 mL  of cells with test compounds at 37 ◦C for 10 min
before the addition of 25 nM calcein-AM. The final concentration of
DMSO was 0.2% (v/v). Calcein incubation was performed for 30 min.
The reaction was stopped by adding 3 mL  of ice-cold PBS buffer.
The cells were collected, washed again with PBS, and resuspended
in ice-cold PBS containing 1% paraformaldehyde. Cell fluorescence
was detected using a BD Accuri C6 flow cytometer (BD Biosciences,
San Jose, CA). Excitation and emission wavelengths used were 480
and 533/30 nm,  respectively. Fluorescence intensity was  expressed
as the mean value of 10,000 events. Treatments were performed in
duplicate.
2.5. Doxorubicin accumulation assay
HEK293T cells were plated on poly-d-lysine-coated cover glass
placed in a 6-well plate at a density of 3 × 105 cells/well in
2 mL  culture medium. The next day, MRP1-GFP expression vec-
tor was transiently transfected into HEK293T cells using jetPRIME
Transfection Reagent (Polyplus-transfection SA, Illkirch, France)
according to the manufacturer’s instructions. After 24–48 h, cells
were pre-treated with 10 M test compound for 30 min, followed
by doxorubicin treatment (10 M)  for 1 h. Confocal microscopy
was performed using a iMIC digital microscope (TILL Photonics
GmbH, Gräfelfing, Germany) equipped with a 1.35 numerical aper-
ture 60× oil-immersion objective. Excitation was performed at
488 nm for GFP and doxorubicin, with emission bands of 475/42
and 605/64 nm, respectively. Images were processed using ImageJ
(NIH, Bethesda, MD).
2.6. Resistance reversal assay
Sensitivity of H69 and H69AR cells to vincristine and the ability
of test compounds to reverse the resistance of H69AR cells against
vincristine were analyzed using the MTT  colorimetric assay. Cells
were seeded in 96-well plates (CellBIND
®
, Corning) at 2.5 × 104
cells per well in 100 L culture medium. After 24 h, 50 L of test
compound at selected concentration prepared in culture medium
was added to the cells. After 1 h, 50 L of vincristine at varying con-
centrations was  added to the cells. Final DMSO concentration was
at 0.5%. Cells were incubated for 96 h. At the end of the incubation
period, 100 L of culture medium was carefully removed and cells
were treated with MTT  (0.45 mg/mL) for 4 h. The formazan crystals
were dissolved by the addition of 100 L 15% SDS containing 10 mM
HCl and absorbance at 570 nm were recorded using a Hidex Sense
Beta Plus plate reader (Turku, Finland). Treatments were performed
in triplicate.
2.7. Membrane vesicle preparation
Membrane vesicles were prepared as previously described with
modifications [34]. Membrane vesicles were prepared from sta-
ble (HEK293/MRP1 and HEK293/MRP3) or transiently transfected
(HEK293T/MRP2 and HEK293T/MRP4) cell lines. Cell pellets frozen
at −80 ◦C were thawed and resuspended in buffer containing
50 mM Tris.HCl, pH 7.4, 250 mM sucrose, 0.25 mM CaCl2, and 1×
complete protease inhibitors (Santa Cruz Biotechnology, Dallas,
TX), and then disrupted by nitrogen cavitation at 450 psi for 5 min.
The lysates were supplemented with 1 mM EDTA and centrifuged
at 500 × g at 4 ◦C for 10 min. The supernatant was collected and the
cell pellet was resuspended and centrifuged again to collect the sec-
ond supernatant. Pooled supernatant was layered over 35% (w/w)
sucrose containing 10 mM Tris.HCl, pH7.4, and 1 mM EDTA and cen-
trifuged at 25,000 rpm at 4 ◦C for 1 h in a SW28 rotor (Beckman
Coulter, Brea, CA). The opaque membrane interface was  collected
and washed twice by ultracentrifugation. The membrane pellet
was resuspended in transport buffer (50 mM Tris.HCl, pH 7.4, and
250 mM sucrose) and passed 20 times through a 27-gauge needle
for vesicle formation. Protein concentration was determined using
Quick Start Bradford Protein Assay (BioRad, Hercules, CA).
2.8. Membrane vesicular transport assay
ATP-dependent transport of [3H]E217G into the inside-out
membrane vesicles was measured by a rapid filtration tech-
nique [34]. MRP-enriched membrane vesicles (2 g protein) were
incubated with 400 nM/20 nCi [3H]E217G for 1 min (MRP1) or
400 nM/50 nCi [3H]E217G for 5 min  (MRP2-4) in a 30-L reaction
mixture containing 4 mM AMP  or ATP, 10 mM MgCl2, and test com-
pound in transport buffer (250 mM sucrose and 50 mM Tris-HCl, pH
7.4). Reactions using MRP2-4 membrane vesicles also contained
10 mM creatine phosphate and 100 g/mL creatine phosphokinase
for ATP regeneration. Final DMSO concentration in the reaction was
0.29%. Reaction was  stopped by adding ice-cold transport buffer.
The resulting mixture was  transferred to a 96-well MultiScreenHTS-
FB plate (EMD Millipore, Billerica, MA). Under vacuum aspiration,
filter membranes were washed with 4 × 200 L ice-cold suspension
buffer. Radioactivity retained on the membranes was  measured
using a Tri-Carb 4810TR liquid scintillation counter (PerkinElmer,
Waltham, MA). Treatments were performed in triplicate. ATP-
dependent uptake was calculated by subtracting the uptake in the
presence of AMP  from the uptake measured in the presence of ATP.
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2.9. Fluorescence spectroscopy
Fluorescence spectroscopy experiments were carried out using
the Fluorimeter Model FL3-11 (HORIBA Edison, New Jersey). Mem-
brane vesicles were prepared from stably transfected HEK293
cells expressing either GFP-MRP1 (donor control containing only
GFP) or two-color MRP1 (containing both GFP and RFP fused to
MRP1). Steady-state fluorimetry was employed for ligand-free
(apo) and ligand-induced intramolecular fluorescence resonance
energy transfer (FRET) analysis using experimental conditions
described by (Verhalen et al., 2011) with modifications. Membrane
vesicles (10 g) in Tris sucrose buffer (250 mM Tris, 50 mM  sucrose,
pH 7.4) were prepared and pre-incubated with 10 M of test com-
pounds for 20 min  at 37 ◦C in a water bath prior to spectroscopy
experiment. GFP excitation was accomplished at 480 nm and RFP
was excited at 530 nm.  Emission for both GFP and RFP with integra-
tion time of 3 s was recorded at 480–650 nm.  Emission scan of the
donor only (GFP-MRP1 sample) was first collected while monitor-
ing average donor emission peak intensity. Emission scan was then
collected in the apo condition (ligand-free two-color MRP1); donor
quenching was monitored and the average donor emission peak
intensity was recorded. The test compound conditions were simi-
larly scanned and donor quenching monitored. Each emission scan
was collected at an interval of 5 nm every 3 s for a total of 10 min.
Experiments were performed in triplicates. The relative fluores-
cence of the donor in the presence and absence of the acceptor was
used to analyze data. The ratio of the average donor emission peak
intensity (in counts per second, cps) in the donor-acceptor sample
(two-color MRP1) to the average donor emission peak intensity in
the donor only control (GFP-MRP1) was used to calculate the FRET
efficiency of apo and compound-induced conditions.
2.10. High-content screening data analysis
The MetaXpress software provides the average fluorescence
intensity value for each well, which is calculated from the fluores-
cence intensity values collected from the generated segmentation
masks in the 4 captured images. The relative inhibition of each
test compound on calcein-AM efflux was determined for each well
using the following equation:
%inhibition = XT − Xcalcein−AM
XMK−571 − Xcalcein−AM
× 100,
where X represents the average fluorescence intensities and T rep-
resents the test compound. Positive and negative controls were
placed in every two columns and used for the determination of the
percent inhibition for compounds within the same columns. The
Z’-factor, a parameter commonly used to reflect assay performance
[31], was determined with the following equation:
Z ’-factor = 1 − 3 (MK−571 + calcein)|MK−571 − calcein|
,
where  and  denote the standard deviations and means, respec-
tively.
2.11. Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics
19 (IBM, Armonk, NY). The differences between mean values were
analyzed using linear mixed model analysis. Sidak correction was
applied for multiple comparisons. Statistical testing was performed
at 5% level of significance.
3. Results
3.1. Assay development and optimization
With ImageXpress High-Content Screening System, calcein-AM
was used as a substrate for developing an imaging-based high-
throughput screening efflux assay for MRP1. The H69AR cell line,
which is a doxorubicin-selected MDR  lung cancer cell line that
expresses high levels of MRP1 [9], and its parental H69 cell line,
were used for the development of this assay. Calcein-AM is a cell
permeable and nonfluorescent compound that turns into highly
fluorescent molecule after the acetoxymethyl ester (AM) moiety is
cleaved off by cellular esterases. Calcein-AM is a well-known sub-
strate for MRP1 and P-glycoprotein. In contrast to P-gp, MRP1 can
also efflux the fluorescent anionic free calcein. The basic concept is
that cells with no or very low expression levels of endogenous MRP1
and other transporters capable of effluxing calcein are expected
to accumulate high levels of fluorescent calcein. In contrast, cells
over-expressing MRP1 will show no or very little fluorescent calcein
accumulation under similar experimental conditions due to active
calcein efflux. For the quantification of fluorescence intensities in
acquired images, we  used a custom module in the MetaXpress soft-
ware, which identifies cells by object segmentation on the FITC
channel. Fig. 1 illustrates representative brightfield, fluorescent,
and segmentation mask images of H69AR cells treated with calcein-
AM.  The MetaXpress software provides various built-in custom
modules for object-based segmentation. Among the available cus-
tom modules, we  selected the ‘Find Blobs’ module as the optimum
module after manually comparing (1) the fitness and robustness
of segmentation masks and (2) the processing time required to
analyze data collected from one plate.
The strategy for the screening assay was to identify the con-
ditions where H69AR cells would show little or no fluorescent
substrate accumulation inside the cells due to efflux activity of
the transporter. In contrast, high fluorescent substrate accumu-
lation would be expected with MRP1 inhibition. To optimize the
assay conditions for MRP1 using calcein-AM as substrate, we
tested a range of calcein-AM concentrations (1 nM–1000 nM)  and
incubation times (30–180 min) using both parental H69 and MRP1-
overexpressing H69AR cells. As shown in Fig. 2A, H69 cells show
much higher fluorescence accumulation with increasing substrate
concentration as compared with H69AR cells. To test if the differ-
ence observed between the two  cell lines is specifically due to MRP1
efflux activity, effect of MK571 (a well-known MRP1 inhibitor) was
observed at different calcein incubation times. As shown in Fig. 2B,
there is no significant difference in calcein accumulation with or
without MK571 in H69 cells at any calcein incubation time point. In
contrast, MRP1-overexpressing H69AR cells exhibited high calcein
accumulation with MK571 treatment compared with untreated
H69AR cells at all calcein incubation time points (Fig. 2C). These
data demonstrate the feasibility of using H69AR cells to develop a
robust assay for high-throughput screening to identify inhibitors of
MRP1 using calcein-AM as substrate.
3.2. Anti-cancer compound library screening for MRP1 inhibitors
Having successfully developed and optimized the high-content
imaging-based assay, we  sought to identify MRP1 inhibitors within
a library of 386 anti-cancer small molecules under clinical trials for
12 different types of cancers. We screened the library using H69AR
cells and calcein-AM as substrate. Screening was performed in the
96-well format in three independent experiments. Treatment with
MK571 (50 M)  was  used as 100% inhibition for calculating per-
cent inhibition for the test compounds. As shown in Fig. 3, the
relative MRP1-inhibitory activities of each anti-cancer agent from
three experiments were plotted as a 3D scatter graph. We  defined a
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Fig. 1. Imaging-based detection of calcein accumulation. H69AR cells were treated with 0.25 M calcein-AM and 50 M MK571 for 1 h. Bright-field and fluorescent images
were  acquired using the ImageXpress Micro XLS Widefield High-Content Analysis System. Segmentation masks were generated using the MetaXpress software. Bar = 50 m.
Table 1
Chemotherapeutic targets, % inhibition, and IC50 values for calcein accumulation inhibition for identified MRP1 inhibitors.
Compound Chemotherapeutic Target % Calcein Control Inhibitiona IC50b (M)
MK-571 100.0 ± 0 8.4 ± 1.8
Tipifarnib (Zarnestra) Transferase 199.1 ± 56.8 3.7 ± 0.4
AZD1208 Pim 145.7 ± 25.3 0.7 ± 0.2
Rapamycin (Sirolimus) Autophagy 142.5 ± 12.2 2.8 ± 0.5
Deforolimus (Ridaforolimus) mTOR 111.9 ± 19.4 4.9 ± 0.9
HS-173  PI3K 94.0 ± 21.8 4.6 ± 1.5
YM201636 PI3K 81.9 ± 4.9 2.0 ± 0.2
ESI-09  74.6 ± 11.8 3.4 ± 0.1
Everolimus (RAD001) mTOR 72.6 ± 7.8 2.6 ± 0.1
TAK-733 MEK 67.4 ± 12.7 8.5 ± 1.2
CX-6258 Pim 57.1 ± 16.4 c
Cyclosporin A 50.2 ± 2.7 6.6 ± 1.7
Temsirolimus (Torisel) mTOR 43.3 ± 4.2 5.6 ± 0.1
a Mean ± SEM of n = 3 independent experiments.
b Mean ± SEM of n = 2 independent experiments.
c Unable to generate IC50 value at the tested concentration range.
positive hit as a compound that exhibits ≥40% mean percent inhibi-
tion. By applying this cut-off value, 13 compounds were identified
as potential MRP1 inhibitors. These are displayed as green dots in
the 3D plot. Identified MRP1 hits, together with their therapeutic
targets and percent inhibition are shown in Table 1. Among the
identified compounds, cyclosporine A and rapamycin are known
MRP1 inhibitors [35,36], while the others, to the best of our knowl-
edge, have not been reported to inhibit MRP1 efflux function. The
reproducibility of the screening assay was reflected by the corre-
lations between any two experiments, which are in the range of
0.86–0.94, indicating a good reproducibility. The performance of
the assay was also assessed by deriving the Z’-factor from the exper-
iments. The average Z’-factor across all plates was  0.63, indicating
a good assay performance.
3.3. Validation of identified MRP1 inhibitors
To verify the inhibitory activities of the hit compounds obtained
from the initial high-content screening and to identify any false
hits or auto fluorescent compounds, we performed concentration-
response studies using the same high-content imaging-based
calcein efflux assay with compound concentrations ranging from
0.4 to 50 M.  One of the compounds, deltarasin, was excluded from
further studies as we did not observe concentration-dependent
inhibition of calcein efflux, possibly due to its cytotoxic effect (data
not shown). We  were also unable to obtain a sigmoidal concen-
tration response curve and the corresponding IC50 value for the
compound CX-6258, due to a cytotoxic effect at higher concen-
trations. Chemical structures of the positive hits are shown in
Fig. 4. As shown in Fig. 5, 11 of the identified MRP1 inhibitors
exhibit sigmoidal concentration-dependent inhibition of calcein
efflux. JNJ-26854165, a compound that did not inhibit MRP1 in the
initial screen was also included as a negative control and exhibited
no modulatory effect on calcein efflux at the tested concentration
range. As detailed in Table 1, IC50 values in the low micromo-
lar range of 0.7–8.5 M were displayed by the tested compounds,
which are comparable to MK571 (IC50 = 8.4 ± 1.8 M).  Next, we
examined if the MRP1-inhibitory activity of the identified com-
pounds can be reproduced in the traditional flow cytometry-based
calcein accumulation assay. To this end, H69 and H69AR cells were
pre-treated with the test compounds for 10 min  before incuba-
tion with calcein for 30 min. As shown in Fig. 6A, MK571 at 50 M
enhanced calcein accumulation in H69AR cells by 12.7-fold. All of
the identified compounds (10 M)  also significantly increased cal-
cein accumulation in H69AR cells by 6.6–13.0-fold, but not in H69
cells. Test compounds AZD1208, YM201636, and everolimus were
the most potent calcein efflux inhibitors and increased calcein accu-
mulation by 13.0-, 10.5-, and 10.8-fold, respectively. In contrast,
JNJ-26854165, which was used as a negative control, did not result
in an appreciable change of calcein accumulation in both cell lines.
To investigate if the identified MRP1 inhibitors modulate the
efflux of other MRP1 substrates besides calcein, we studied the
effects of the compounds on MRP1-mediated efflux of a com-
monly used anticancer drug, doxorubicin, a well-known substrate
of MRP1. HEK293T cells were transiently transfected with MRP1-
GFP encoding vector and confocal microscopy was used to visualize
the inhibitory effect of the test compounds on MRP1-mediated
doxorubicin efflux in live cells. As shown in Fig. 6B, cells treated
with DMSO showed high doxorubicin accumulation in the nuclei
of non-transfected cells, while doxorubicin fluorescence was very
low or undetectable in cells expressing MRP1-GFP. MRP1-mediated
efflux of doxorubicin was  reduced by MK571 (50 M)  but not
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Fig. 2. Concentration- and time-dependent accumulation of calcein in H69 and H69AR cells. A. H69 and H69AR cells were treated with calcein-AM at various concentrations
(0.001–1 M)  for 1 h. Representative images of calcein-AM treatment at 0.03, 0.1, 0.3, and 1 M are shown. The average fluorescence intensities derived from the fluorescent
images  were graphed and shown on the right. B. H69 cells were treated with 0.25 M calcein-AM in the absence and presence of 50 M MK571 for 15–180 min. Representative
images  of calcein treatment at 30, 60, 90, and 120 min  are shown. C. H69AR cells were treated with 0.25 M calcein-AM in the absence and presence of 50 M MK571 for
15–180  min. Representative images of calcein treatment at 30, 60, 90, and 120 min  are shown. Data are representative of two experiments and shown as mean ± SD (n = 3).
JNJ-26854165 (10 M),  which were used as positive and nega-
tive controls, respectively. All the test compounds (10 M)  appear
to induce doxorubicin accumulation in MRP1-expressing cells to
a certain extent, with tipifarnib, AZD1208, deforolimus, HS-173,
and YM201636 showing strong inhibition, while rapamycin, ESI-09,
everolimus, TAK-733, CX-6258, cyclosporine A, and temsirolimus
showing moderate to mild inhibition.
3.4. Resistance reversal by selected MRP1 inhibitors
The anti-cancer agent library used in this study contains small
molecules currently under clinical investigation for different ther-
apeutic targets, such as mTOR and PI3K. We  were interested to
investigate if the identified MRP1 inhibitors can reverse drug resis-
tance in an MDR  cell line. Such property may  be valuable in
treatment of cancers with prominent MRP1 expression. We  first
performed concentration response using the identified compounds
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Fig. 3. Reproducibility of the imaging-based MRP1-mediated calcein accumulation
screening assay. Screening of the anti-cancer compound library was  performed in
three independent experiments at compound concentration of 10 M.  The relative
inhibitory activities of each compound were calculated and displayed as a 3D plot.
Green dots represent compounds with mean percent inhibition of ≥40%. The table
below the plot shows correlation coefficients between any two experiments. 3D
scatter plot was generated using Matplotlib 1.5.1 and correlation coefficients were
calculated using MS Excel.
in H69AR to evaluate the cytotoxicity of the compounds (data not
shown). Selected compounds at non- or minimal cytotoxic con-
centrations were then administered to H69AR cells in combination
with increasing concentrations of vincristine, a commonly used
chemotherapeutic agent. As shown in Fig. 7, H69 cells (dotted
blue) exhibited a much greater sensitivity towards vincristine than
H69AR cells (solid red). MK571, tipifarnib, AZD1208, rapamycin,
deforolimus, everolimus, TAK-733, and temsirolimus at indicated
concentrations reversed the resistance of H69AR cells against vin-
cristine to various extents. IC50 values and fold resistance of H69AR
cells treated with vincristine with or without the selected com-
pounds are shown in Table 2. In the absence of any MRP1 inhibitor,
H69AR cells were 43.6-fold more resistant than the parental H69
cells against vincristine. The standard MRP1 inhibitor MK571 at
10 M reduced the resistance of H69AR cells to 19.4-fold. Compa-
rably, tipifarnib, AZD1208, deforolimus, and temsirolimus reversed
the resistance of H69AR cells against vincristine to 11.6–22.1-fold.
On the other hand, rapamycin, everolimus, and TAK-733 resulted in
stronger reduction in fold resistance (≤10-fold). These data indicate
that the identified MRP1 inhibitors may  be potent MDR  reversal
agents, which can be studied for their effectiveness in overcoming
clinical MDR  where MRP1 expression is directly linked to a poor
clinical outcome.
Table 2
The effects of selected MRP1 inhibitors on the IC50 values of vincristine in H69  and
H69AR cells.
Cells/Treatment IC50a (nM) Fold resistanceb
H69 0.5 ± 0.2 1.0
H69AR 23.1 ± 3.0 45.5
H69AR + MK571 10 M 9.8 ± 0.4 19.4
H69AR + Tipifarnib 1 M 6.4 ± 0.3 12.7
H69AR + AZD1208 2 M 11.4 ± 0.7 22.6
H69AR + Rapamycin 10 M 4.0 ± 0.9 7.8
H69AR + Deforolimus 10  8.7 ± 1.1 17.1
H69AR + Everolimus 10 M 6.6 ± 1.9 13.1
H69AR + TAK-733 10 M 5.5 ± 0.5 10.8
H69AR + Temsirolimus 10 M 9.0 ± 0.6 17.7
aMean ± SEM of n ≥ 3 independent experiments.
bFold resistance is the ratio between IC50 value of each treatment and IC50 value of
vincristine alone in H69 cells (0.5 ± 0.2).
3.5. Differential effects of hit compounds on E217ˇG vesicular
uptake by MRP1-4
Several other members of the MRP  (ABCC) sub-family, like
MRP1, hold important roles in regulating drug absorption and
disposition in different organs [11]. We were interested to inves-
tigate whether the MRP1 inhibitors identified in our study also
exert a modulatory activity on other MRPs and learn about their
selectivity towards closely related sub-family members. To this
end, we prepared membrane vesicles from HEK293 cells stably
or transiently expressing MRP1-4 and evaluated the effects of
the compounds on the uptake of E217G, a common MRP sub-
strate, into the membrane vesicles. As shown in Fig. 8, uptake of
[3H]E217G into MRP1-4 membrane vesicles was reduced by more
than 50% with 10 M MK571, a pan-MRP inhibitor. Another known
broad-spectrum MRP  inhibitor, cyclosporine A, also displayed sig-
nificant inhibition of [3H]E217G uptake across MRP1-4 membrane
vesicles. In addition, the mTOR inhibitors, rapamycin and its deriva-
tives deforolimus, everolimus, and temsirolimus appear to be
pan-inhibitors for MRP1-4, effectively reducing [3H]E217G uptake
across MRP1-4 membrane vesicles. In terms of compound effects
on MRP1-mediated transport of E217G, all of the hit compounds
except TAK-733 resulted in a significant decrease in the uptake of
[3H]E217G into MRP1 membrane vesicles. Tipifarnib, rapamycin,
deforolimus, ESI-09, everolimus, CX-6258, and temsirolimus inhib-
ited [3H]E217G uptake by more than 50%, while AZD1208 and
YM201636 showed inhibitory activity in the range of 20–50%. ESI-
09 was the most potent inhibitor of [3H]E217G uptake by MRP1,
reducing the update by 90%. Interestingly, two of the hit com-
pounds, namely tipifarnib and ESI-09, resulted in 2.2- and 2.1-fold
stimulation of [3H]E217G uptake, respectively, into MRP2 mem-
brane vesicles. HS-173, YM201636, and CX-6258 also displayed
a mild stimulatory effects of 17, 29, and 16%, respectively on
MRP2-mediated transport, although the results are not statistically
significant. In MRP3 membrane vesicles, tipifarnib is the only com-
pound apart from cyclosporine A and rapamycin and its derivatives
that exerted a significant inhibitory effect on [3H]E217G uptake. In
contrast, all of the test compounds exhibited a significant inhibitory
activity on [3H]E217G uptake into MRP4 membrane vesicles.
3.6. Identified hit compounds directly interact with MRP1
We recently introduced a novel structural-based approach for
the screening of drug libraries for interactions with ABC trans-
porters by genetically engineering a two-color MRP1 protein that
is capable of detecting direct interaction of drug molecules with
MRP1. This approach is based on fusing a GFP and RFP with MRP1
to yield a modified two-color recombinant protein, which reports
changes in intramolecular FRET efficiency as an index of MRP1 con-
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Fig. 4. Chemical Structures of selected compounds.
formational changes upon ligand binding [58]. In the present study,
we used fluorescence spectroscopy approach to determine changes
in FRET efficiency of the two-color MRP1 protein upon interaction
with the hit compounds. Our results indicate that MK571, a known
MRP1 inhibitor, produced ∼8% increase in FRET efficiency relative
to the apo condition (Fig. 9). Similarly, all of 12 test compounds
caused an increase in FRET efficiency relative to the basal FRET
level of the apo protein reflecting direct interaction with MPR1. In
contrast, JNJ-26854165, which did not induce MRP1 inhibition in
functional assays also did not produce any significant FRET change
relative to the apo FRET levels. Among the hit compounds, tipifarnib
showed the smallest FRET change (∼2.5%) and deforolimus induced
the largest FRET change (∼9%).
4. Discussion
MRP1 predominantly localizes at the basolateral membranes
of epithelial cells and plays an important role in regulating the
absorption and distribution of various xenobiotics, including many
therapeutic agents and toxins. For tissues with epithelial basolat-
eral membranes confronting the blood circulation, MRP1 limits the
entry of blood-borne xenobiotics and thus lower their bioavailabil-
ity or potential toxic effects. For instance, Mrp1 knockout mice
show greater sensitivity towards damages of the oropharyngeal
mucosal layer and the testicular tubules induced by etoposide,
an anti-cancer agent [37]. Therefore, profiling the interactions
between therapeutic agents and MRP1 represents an important
aspect in predicting and determining drug bioavailability and
drug–drug interactions mediated by MRP1. In addition, MRP1
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Fig. 5. Concentration response curves of positive hits identified from initial screening. H69AR cells were pre-treated with indicated compounds at concentrations from 0.4 to
50  M for 30 min  before treatment with 0.25 M calcein-AM for 1 h. One of the identified compounds, deltarasin, did not exhibit concentration-dependent inhibition (data
not  shown) and was  excluded from further studies. JNJ-26854165 was  not an initial positive hit and included as a negative control.
is associated with clinical MDR  of several types of cancers. Re-
sensitization of resistant malignancies using MRP1 inhibitors
remains a possible avenue in overcoming MDR  in chemotherapy,
especially in cancers where MRP1 expression is clearly associated
with a poor clinical outcome.
In this study, we have developed and validated a high content
imaging-based high-throughput assay for the detection of MRP1
inhibition via calcein efflux in an MRP1-overexpressing cell line
and performed screening of an anti-cancer agent library using this
assay. Based on three independent screenings, the assay demon-
strated very high correlation (0.86–0.94) among replicates. The
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Fig. 6. Validation of MRP1-inhibitory activity of identified compounds. A. H69 and H69AR cells were pre-treated with 50 M MK571 or 10 M test compounds for 10 min
before  treatment with 25 nM calcein-AM at 37 ◦C for 30 min. Fluorescence intensities of intracellular calcein were detected using flow cytometry, with excitation and emission
wavelengths of 480 and 533/30 nm,  respectively. Data are combined from two  experiments and presented as mean ± SEM. *, p < 0.05 compared with control; #, excluded due
to  significant change in cell scatter. B. HEK293T cells transiently transfected with MRP1-GFP (green) were pre-treated with 10 M test compounds, before treatment with
doxorubicin (red) at 37 ◦C for 1 h. Images were acquired using confocal microscopy. GFP and doxorubicin were excited at 488 nm,  and detected at 475/42 and 605/64 nm,
respectively.
Fig. 7. Reversal of drug resistance towards vincristine in H69AR cells by selected identified MRP1 inhibitors. H69 and H69AR cells were treated with vincristine at increasing
concentrations in the absence and/or presence of selected MRP1 inhibitors. MK571, rapamycin, deforolimus, everolimus, TAK-733, and temsirolimus were at 10 M.  Tipifarnib
and  AZD1208 were at 1 and 2 M,  respectively. After 72 h, cell viability was  evaluated with MTT. Data are representative of two experiments and presented as mean ± SD
(n  = 3).
high quality and efficiency of this high-throughput screening assay
was also reflected by Z’-factor of 0.63 (across all plates). The
imaging-based efflux assay described in this study has several
advantages over assays based on fluorescent plate readers and flow
cytometry. In terms of sensitivity, the imaging-based assay is supe-
rior to assays based on fluorescent plate reader, which is more
suited for assays performed in a homogenous condition [30]. Addi-
tionally, unlike assays based on flow cytometry, cells can be imaged
in situ without the need of preparing cell suspension and perform-
ing multiple washing steps, which increase the processing time and
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Fig. 8. Effects of test compounds on [3H]E217G uptake into MRP1, 2, 3, and 4 membrane vesicles. Membrane vesicles were prepared from stable HEK293/MRP1 and
HEK293/MRP3 cells or transiently transfected HEK293T/MRP2 and HEK293T/MRP4 cells. Membrane vesicles (2 g protein) were incubated with 10 M test compounds.
For  vesicular transport into MRP1 membrane vesicles, reactions were performed using 400 nM/20 nCi [3H]E217G at 37 ◦C for 1 min. For studies using MRP2-5 membrane
vesicles, reactions were performed using 400 nM/50 nCi [3H]E217G at 37 ◦C for 5 min. Radioactivity retained on collected membrane vesicles was quantified using liquid
scintillation counting. Data are combined from two experiments and presented as mean ± SEM. *, p < 0.05 compared with control.
Fig. 9. Compound induced conformational changes in MRP1. Membrane vesicles
were prepared from stable HEK293/GFP-MRP1 and HEK293/two-color MRP1 cells.
Membrane vesicles (10 g) were incubated with 10 M of each test compound for
20  min at 37 ◦C prior fluorescence spectroscopy using Fluorimeter model FL3-11.
GFP excitation was  accomplished at 480 nm and RFP was  excited at 530 nm.  Emis-
sion for both GFP and RFP with integration time of 3 s was  recorded at 480–650 nm.
GFP excitation was  observed at 480 nm and RFP, at 530 nm.  Emission for both GFP
and RFP was collected at 480–650 nm with 3-s integration time. Data are repre-
sentative of two independent experiments in triplicates. MK571 and JNJ-26854165
were used as positive and negative controls, respectively. To calculate the change
in  FRET efficiency for test compound conditions, the basal apo FTRET efficiency was
subtracted from the compound-induced FRET efficiencies and results are presented
as mean ± SEM.
limit the assay throughput. Furthermore, cell viability and density
before and after treatment can be visually inspected in bright-field
images. This assists in the evaluation of compound cytotoxicity,
which may  interfere with the assay. In this report, although we
collected both bright-field and fluorescent images from the experi-
ments, the automated image analysis requires only the fluorescent
images for the generation of segmentation masks. The processing
time for image acquisition can be considerably reduced if bright-
field images are not collected. This may  be desirable for compound
screening at a much larger scale or for conservation of data stor-
age space. A caveat associated with our assay, however, is a gradual
decrease in fluorescence levels as the plate is read. We  think that
efflux of calcein out of the cells after the treatment removal and
washing step is causing a time-dependent reduction in intracel-
lular calcein levels. Therefore, it is crucial to have controls placed
throughout the plate to account for the fluorescence decrease. In
our screening, one positive and one negative controls were included
in every two  columns so the percent inhibition for each test com-
pound was calculated on a two column basis. It is also possible
to circumvent this issue by reducing the plate reading time by
decreasing the number of images acquired.
Conventional cytotoxic drugs such as doxorubicin, etoposide,
paclitaxel, cisplatin, and methotrexate, which are still commonly
used in chemotherapy, target essential and fundamental cellular
processes (e.g., DNA synthesis, cell division, or DNA damage) that
makes them non-selective and cytotoxic. Major problems associ-
ated with chemotherapy are the development of MDR  and toxicity.
One way  to address these problems is the focus on discovering
new drugs that target cell signaling pathways and are not cyto-
toxic. Several new agents have been discovered that target different
kinases and receptors (e.g. drugs that target tyrosine kinases and
EGF receptor). Another common strategy to improve the efficacy
and reduce the toxicity of chemotherapeutic drugs is through com-
bination therapy, where drugs from different families targeting
different mechanisms are administered together to achieve bet-
ter outcomes. Given the remarkable ability of MRP1 to modulate
the absorption and distribution of a wide spectrum of drugs, it is
very important to profile any new drug candidates for their inter-
action with this transporter. In the present work, we tested the
interactions between MRP1 and anti-cancer agents that are cur-
rently under clinical investigation. We are particularly interested in
anti-cancer candidates, as a positive inhibitory activity on MRP1 not
only suggests a potential application in reversing MRP1-mediated
drug resistance, but may  also indicate a substrate relationship with
MRP1. In the former scenario, the drug candidate may be used as an
anti-cancer agent that can also reverse MRP1-mediated drug resis-
tance. In the latter scenario, the anti-cancer agent might eventually
become ineffective due to MDR  conferred by MRP1 overexpression.
Information on such interactions thus provide insights into the pos-
sible interactions and efficacy of the drugs. In terms of MDR  reversal
in the clinical setting, although no clinical trial aimed at MRP1
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inhibition has been reported, clinical trials using P-gp inhibitors
as chemosensitizers have continued to produce negative results
[38]. In unraveling the failure of translating preclinical and early
clinical successes of P-gp inhibitors into phase III clinical trials,
a few possible explanations have been put forward, notably the
lack of selection of patient population (in which upregulated P-gp
expression in patients is confirmed) and the possible compensatory
increase in drug efflux by other ABC transporters [39]. Therefore,
the potential application of MRP1 inhibitor in sensitizing malig-
nancies where MRP1 expression is prominent, such as primary
neuroblastoma, to chemotherapeutic agents cannot be ruled out. A
combinatorial approach targeting multiple MDR  transporter, such
as P-gp, MRP1, and BCRP, may  also yield a more fruitful outcome if
multiple drug transporters indeed work concertedly in modulating
drug efflux in cancer cells.
Among the 12hit compounds identified in the current study,
cyclosporine A and rapamycin have been previously shown to
inhibit the efflux function of MRP1 [35,36]. Cyclosporin A and
rapamycin are also known to inhibit the transport function of other
ABC drug transporters, including P-gp, BCRP, and MRP2 [36,40].
Three of the novel inhibitors identified in this study, namely
deforolimus, everolimus, and temsirolimus are first-generation
rapamycin analogs (rapalogs) [41]. Rapamycin and rapalogs are
inhibitors of mTOR (mammalian target of rapamycin), an intra-
cellular serine/threonine kinase functioning downstream of the
phosphoinositide 3-kinase (PI3K)/Akt signaling pathway. mTOR
holds essential roles in regulating cell growth, proliferation, and
survival and is dysregulated in various cancers [42]. The use of
rapalogs has shown promising clinical efficacy in several types of
cancers and numerous ongoing clinical trials are using rapalogs as
a single agent or in combination with other anti-cancer agents in
treatments for a wide range of cancers [43,44]. In the present study,
we demonstrated that deforolimus, everolimus, and temsirolimus
are pan-inhibitors of MRP1-4. These rapalogs have also been shown
to be inhibitors of P-gp [33]. Therefore, like cyclosporine A, they are
likely to be broad-spectrum inhibitors of ABC drug transporters.
Whether these rapalogs exert the inhibitory activity by competitive
binding and are thus substrates of ABC drug transporters remains
to be elucidated. If the rapalogs are indeed substrates of ABC drug
transporters, they will be at risk for multidrug resistance inter-
ference mediated by these transporters. In addition, everolimus
has also been reported to downregulate the expression levels of
MRP1 in a cisplastin-resistant gastric cancer cell line [45]. It is
possible that the downregulation by everolimus is achieved by the
disruption of the PI3K/Akt pathway, which has been demonstrated
to modulate the expression of MRP1 in human acute myelogenous
leukemia [46]. It is interesting to note that among the tested
compounds, rapamycin was the most successful in reversal of
H69AR cells resistance towards anti-cancer drug vincristine (IC50
value decreased from 23.1 to 4.0 nM). Everolimus, deforolimus,
and temsirolimus also decreased resistance of H69AR cells against
vincristine to IC50 values of 6.6, 8.7, and 9 nM,  respectively.
Among the identified novel MRP1 inhibitors, HS-173 and
YM201636 are potent PI3K inhibitors that are being actively inves-
tigated for their anti-cancer efficacy [47,48]. It will be of interest to
investigate if these PI3K inhibitors modulate the expression level
of MRP1, besides inhibiting its transport function. The observation
that certain small molecules can modulate not only the efflux activ-
ity but also the expression or degradation of ABC drug transporters
has led to the possibility of sensitizing ABC transporter-mediated
MDR  by exploiting these alternative mechanisms. For instance, PZ-
39 and several related compounds have been reported to effectively
induce the endocytosis and trafficking of BCRP to lysosomes for
degradation, in addition to inhibiting its transport function [49].
The effectiveness of such dual-mode inhibitor of ABC transporters
in clinical chemotherapy is yet to be verified but certainly worth
exploring. Two of the identified MRP1 inhibitors, AZD1208 and
CX-6258 are potent pan-Pim kinase inhibitors and have shown
promising preclinical chemotherapeutic efficacy [50,51]. Interest-
ingly, the Pim-1 kinase has been reported to interact with and
promote the functions of P-gp and BCRP. Phosphorylation of BCRP
by Pim-1 kinase accommodates the multimerization of BCRP in
a prostate cancer cell line whereas phosphorylation of P-gp by
Pim-1 enables glycosylation and surface expression of P-gp besides
protecting it from proteasomal degradation [52,53]. In both cases,
inhibition of Pim-1 kinase either by gene knockdown or chemi-
cal inhibitor resensitizes resistant cells to chemotherapeutic agents
[52,53]. Hence, it will be of interest to investigate if Pim kinase mod-
ulates the expression and degradation of MRP1, and if inhibition of
Pim kinase by AZD1208 and CX-6258 can abolish MRP1-mediated
MDR  through these mechanisms.
In order to investigate the effects of the identified hit compounds
on closely related MRP  family members, vesicular transport stud-
ies were conducted by measuring the uptake of [3H]E217G by
MRP1-4. Our results indicate some selectivity towards the target
transporters as well as differential modulation of transport activity
by the hit compounds. For instance, while most of the compounds
exhibited an inhibitory effect, tipifarnib and ESI-09 notably poten-
tiated the uptake of [3H]E217G by MRP2. Stimulation of MRP2-
mediated uptake has been previously reported in other studies.
For instance, a panel of drugs including indomethacin, probenecid,
sulfinpyrazone, and sulfanitran strongly stimulate the uptake of
E217G in MRP2-overexpressing Sf9 membrane vesicles, while the
efflux of anti-cancer agents paclitaxel and docetaxel by MRP2 in the
polarized MDCKII (Madin-Darby canine kidney) cells is substan-
tially stimulated by probenecid [54,55]. As MRP2 is a drug efflux
transporter with clinical importance [56], stimulation of MRP2 by
tipifarnib and ESI-09 could give rise to clinically relevant drug–drug
interactions where the bioavailability of a co-administered MRP2
substrate drug could be unfavorably decreased. However, it should
be noted that whether a test compound stimulates or inhibits
MRP2 in the vesicular transport assay can be probe-dependent.
Such complexity in MRP2-mediated transport is highlighted in a
study by Kidron et al., in which five out of eight test compounds
exhibit different effects (stimulatory, inhibitory, or ineffective) on
MRP2-mediated transport depending on whether LTC4, E217G, or
5(6)-carboxy-2,7-dichlorofluorescein is used as the probe substrate
[57]. Therefore, further interpretation and studies on the effects of
tipifarnib and ESI-09 on MRP2 will need to take into account the
possible probe-dependent differences. In addition, it is noteworthy
that HS-173, YM201636 (PI3K inhibitors) and AZD1208, CX-6258
(pan-Pim kinase inhibitors) showed inhibition of E217G transport
by MRP1 and MRP4 but not by MRP2 and MRP3.
In summary, we demonstrated the effectiveness of the high
content imaging-based MRP1-inhibition assay to study compound
interaction with MRP1. This paves the way for further screen-
ing methods for the high throughput functional studies of MRP1,
such as compound effect on MRP1 expression and trafficking using
the imaging-based system. We  also identified novel inhibitors of
MRP1 and demonstrated their ability to reverse drug resistance in
MRP1-overexpressing cells. Anti-cancer agents that show a lack of
interaction with MRP1 in our study might also be at lower risk of
being interfered by MRP1-mediated MDR.
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